ViceMinister LIU Yanhua met with President Abbas Hussain of Emerging Markets and President Jean Stéphenne of Biologicals from GlaxoSmithKline (GSK) on March 31st, 2009.

LIU introduced the development plan and policies related to biomedicine in China. According to him, R&D expenditure on biotechnology including biomedicine from2006 to 2010 amounted to RMB10 billion yuan. MOST encouraged multinational corporations to participate in these R&D programs. Considering the large population and uneven economic development in China, quality and affordability of medicine should be guaranteed.

GSK is planning to invest in vaccine R&D and introduceto China flu vaccine adjuvant and cervical cancer vaccines.